Skip to main content
BH

Biolockey Healthworks

This company develops proprietary Nanobody tools to power novel diagnostic products and cellular assays. They offer an accelerated discovery platform for end-to-end Nanobody development, including optimization for affinity and potency. Their focus includes delivering point-of-care diagnostics, such as a multi-marker test for HPV detection.

Bengaluru, IndiaFounded 20235700+ followers
Updated 4 months ago

Funding

$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Cervical cancer screening in India faces challenges due to limited access to traditional laboratory-based HPV testing, hindering early detection and timely treatment of high-risk HPV infections. Current screening methods often require specialized equipment and trained personnel, creating barriers for widespread implementation, especially in resource-limited settings.

Solution

BioLOCKEY is developing a point-of-care diagnostic test for HPV detection, utilizing its proprietary Nanobody Discovery Platform (NanoDx). This multi-marker test aims to provide rapid and accurate results for high-risk HPV types (HPV16/18/31/33/45) directly at the point of care. The NanoDx platform facilitates the accelerated discovery and development of Nanobodies, which are then integrated into diagnostic products. This approach enables accessible cervical cancer screening, particularly in regions where traditional lab infrastructure is lacking.

Target Audience

The primary target audience includes healthcare providers and women in India who require accessible and rapid cervical cancer screening solutions.

Features

  • Point-of-care multi-marker diagnostic test for HPV detection (HPV16/18/31/33/45)
  • Proprietary Nanobody Discovery Platform (NanoDx) for accelerated Nanobody development
  • Diverse and verified Nanobody libraries for challenging high-value targets
  • Nanobody cellular optimization platform for in-cell targets
  • Flexible vertical for analytical development, optimizing for greater affinity and potency
This profile is AI-generated and may contain inaccuracies.